Popular on EntSun
- Purple Heart Recipient Honored by Hall of Fame Son In Viral Tribute Sparking National Conversation on Service Fatherhood, Healing and Legacy - 199
- Amicly Launches as a Safety-First Social App Designed to Help People Build Real, Meaningful Friendships - 162
- Actor Phillip Steward Featured on The Industry Podcast with James Winborn - 145
- iPOP Alum Jacob Batalon Stars in Amazon Prime's "The Wrecking Crew" - 143
- Primeindexer Google indexing platform launched by SEO Danmark APS - 135
- VENUS Goes Live on CATEX Exchange As UK Financial Ltd Activates The Premier Division Of The Maya Meme's League - 129
- Elder Abuse Case Against Healthy Traditions Owner Raises Questions As To The Dire Reality Of Abuse Against The Last Of The Baby Boomers - 126
- Nieuwe standaard in webdesign: Professionele website laten maken voor het MKB vanaf €249 door Websitepioniers - 116
- The Raiders House Band Wins Prestigious Clio Sports Award for Game Day Innovation - 115
- Progressive Dental & The Closing Institute Partner with Zest Dental Solutions to Elevate Full-Arch Growth and Patient Outcomes - 111
Similar on EntSun
- UK Financial Ltd Tokenized LTNS 1, A $1.1 T Asset-Backed ERC-3643 Security Token with 11 On-Chain Contracts Verifying, Compliant Real-World Value
- The Inner Power of Emotional Self-Leadership
- Dr. Nadene Rose Shares the Secret to True Success: Faith, Obedience, and Divine Purpose
- Award-Winning REALTOR® Paige Coker Joins Corcoran DeRonja Real Estate
- TicTac Group acquires French EdTech company Distrisoft
- Newborn Care Network Introduces Clinical Standard to Bridge the Six-Week Postpartum Gap
- The AAA Metamorphosis: How Global Gaming Is Redefining Production Standards
- Monexplora Explains the Options Mechanics Behind March's Tech Selloff and VIX Surge
- EFA Announces 2026 Editorial Rate Chart
- AI Disruption Meets Marine Scale: Off The Hook YS, Inc. (N Y S E American: OTH) Targets Breakout Growth with NextBoat Launch and Aggressive Expansion
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
EntSun News/10949369
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 3, 2022, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 37,250 shares of Puma common stock to six new non-executive employees.
The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, August 1, 2022, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
More on EntSun News
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
Contacts
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, August 1, 2022, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
More on EntSun News
- Independent Country Artist Kirk Menard Announces New Album Release
- Legal Powerhouses, Dance Drama, and Romance: Meet the New Platform Debuting This April
- Homeowner Prep Announces Strategic Language Shift: Replacing "Renters" with "Future Homeowners" to Inspire Wealth-Building Mindsets
- LiposoMore™ Redefines Bioavailability: Joyful Nutritional Launches High-Performance Liposomal Vitamin C and Iron for the Global Supplement Market
- GDE Tree Services Expands Operations into Sydney, NSW
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
Contacts
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
Filed Under: Business
0 Comments
Latest on EntSun News
- Understanding Unexpected Death: Why Independent Autopsies Matter in Cases Without Clear Cause
- Epic Pictures Group Sets North American Release Date for the Thriller NO ORDINARY HEIST
- New Hair Styles, Cuts, Coloring With Molli's Hair Lab Servicing Amelia, Ohio, Clermont County, OH
- For April Fools' Day: A poem about The Secret to Happiness! The secret is "Don't Say Nuthin'"
- Award-Winning REALTOR® Paige Coker Joins Corcoran DeRonja Real Estate
- Over 98% of crypto owners globally don't declare taxes, new report find
- TicTac Group acquires French EdTech company Distrisoft
- Scientology Network Celebrates International Day of Happiness with Global Marathon
- Comedian Marc Yaffee Headlines Willits High School Sober Grad Fundraiser Show
- NYC Psychic With 8–1 Fight Prediction Record Calls Israel Adesanya Win Before UFC Seattle
- Mark Dobosz Makes Donorassess.org Free To Every Nonprofit On The Planet
- Genpak Announces Closure of Utah Manufacturing Facility
- Isiah Thomas, the IWPA, Chef Sergentakis & Blank Page to Author Join Walden's Book Launch on Liftoff
- Newborn Care Network Introduces Clinical Standard to Bridge the Six-Week Postpartum Gap
- Natural Born Clothing Brand Announces "CALM IS A LUXURY" Spring/Summer 2026 Pop-Up Experience
- Former Ad Guy Delivers a Gripping Political Thriller "Balance of Evil" That Explores Power, Betrayal, and Corruption
- The AAA Metamorphosis: How Global Gaming Is Redefining Production Standards
- Monexplora Explains the Options Mechanics Behind March's Tech Selloff and VIX Surge
- The Podcast Built From a Father's Worst Conversation With His Son
- CarolinaRedd.com Relaunches with Fully Digitized Art Portfolio Showcasing Rapper, Actress, Model